These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35366926)

  • 41. Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer.
    Katz A; Ferrer M; Suárez JF;
    Radiat Oncol; 2012 Nov; 7():194. PubMed ID: 23164305
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
    Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
    Technol Cancer Res Treat; 2010 Dec; 9(6):575-82. PubMed ID: 21070079
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment.
    Alongi F; Rigo M; Figlia V; Cuccia F; Giaj-Levra N; Nicosia L; Ricchetti F; Sicignano G; De Simone A; Naccarato S; Ruggieri R; Mazzola R
    Radiat Oncol; 2020 Mar; 15(1):69. PubMed ID: 32248826
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial.
    Wang K; Chen RC; Kane BL; Medbery CA; Underhill KJ; Gray JR; Peddada AV; Fuller DB
    Int J Radiat Oncol Biol Phys; 2018 Dec; 102(5):1430-1437. PubMed ID: 30056080
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?
    Woo JA; Chen LN; Wang H; Cyr RA; Bhattasali O; Kim JS; Moures R; Yung TM; Lei S; Collins BT; Suy S; Dritschilo A; Lynch JH; Collins SP
    Front Oncol; 2015; 5():77. PubMed ID: 25874188
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results.
    Aluwini S; van Rooij P; Hoogeman M; Kirkels W; Kolkman-Deurloo IK; Bangma C
    Radiat Oncol; 2013 Apr; 8():84. PubMed ID: 23570391
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A multi-institutional phase 2 trial of prostate stereotactic body radiation therapy (SBRT) using continuous real-time evaluation of prostate motion with patient-reported quality of life.
    Jackson WC; Dess RT; Litzenberg DW; Li P; Schipper M; Rosenthal SA; Chang GC; Horwitz EM; Price RA; Michalski JM; Gay HA; Wei JT; Feng M; Feng FY; Sandler HM; Wallace RE; Spratt DE; Hamstra DA
    Pract Radiat Oncol; 2018; 8(1):40-47. PubMed ID: 29304991
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
    Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
    Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.
    Chen LN; Suy S; Wang H; Bhagat A; Woo JA; Moures RA; Kim JS; Yung TM; Lei S; Collins BT; Kowalczyk K; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2014 Jun; 9():148. PubMed ID: 24966110
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prospective Randomized Phase II Study of Stereotactic Body Radiotherapy (SBRT) vs. Conventional Fractionated Radiotherapy (CFRT) for Chinese Patients with Early-Stage Localized Prostate Cancer.
    Poon DMC; Lam D; Wong KCW; Chu CM; Cheung M; Mo F; Suen J; Ng CF; Chan ATC
    Curr Oncol; 2021 Dec; 29(1):27-37. PubMed ID: 35049677
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials.
    King CR; Collins S; Fuller D; Wang PC; Kupelian P; Steinberg M; Katz A
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):939-45. PubMed ID: 24119836
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Pilot Study.
    Parsai S; Juloori A; Sedor G; Reddy CA; Thousand R; Magnelli A; Berglund RK; Stovsky M; Klein EA; Tendulkar RD; Stephans KL
    Am J Clin Oncol; 2020 Jul; 43(7):469-476. PubMed ID: 32349020
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A single-center study of 100 consecutive patients with localized prostate cancer treated with stereotactic body radiotherapy.
    Bolzicco G; Favretto MS; Satariano N; Scremin E; Tambone C; Tasca A
    BMC Urol; 2013 Oct; 13():49. PubMed ID: 24134138
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5 T MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes.
    Mazzola R; Cuccia F; Figlia V; Rigo M; Nicosia L; Giaj-Levra N; Ricchetti F; Vitale C; Mantoan B; Di Paola G; De Simone A; Gurrera D; Sicignano G; Naccarato S; Ruggieri R; Alongi F
    Radiol Med; 2021 Jul; 126(7):989-997. PubMed ID: 33835309
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer.
    Kawakami S; Tsumura H; Satoh T; Tabata K; Sekiguchi A; Kainuma T; Nakano M; Iwamura M; Ishiyama H
    Radiat Oncol; 2022 Apr; 17(1):67. PubMed ID: 35379264
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Computed tomography versus magnetic resonance imaging in high-dose-rate prostate brachytherapy planning: The impact on patient-reported health-related quality of life.
    Harris AA; Wu M; Deirmenjian JM; Shea SM; Kang H; Patel R; Fielder D; Mysz ML; Harkenrider MM; Solanki AA
    Brachytherapy; 2021; 20(1):66-74. PubMed ID: 33160849
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early Exploratory Analysis for Patient-reported Quality of Life and Dosimetric Correlates in Hypofractionated Stereotactic Body Radiation Therapy (SBRT) for Low-risk and Intermediate-risk Prostate Cancer: Interim Results from a Prospective Phase II Clinical Trial.
    Iarrobino NA; Gill B; Sutera PA; Kalash R; D' Ambrosio D; Heron DE
    Am J Clin Oncol; 2019 Nov; 42(11):856-861. PubMed ID: 31584457
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer.
    Oermann EK; Slack RS; Hanscom HN; Lei S; Suy S; Park HU; Kim JS; Sherer BA; Collins BT; Satinsky AN; Harter KW; Batipps GP; Constantinople NL; Dejter SW; Maxted WC; Regan JB; Pahira JJ; McGeagh KG; Jha RC; Dawson NA; Dritschilo A; Lynch JH; Collins SP
    Technol Cancer Res Treat; 2010 Oct; 9(5):453-62. PubMed ID: 20815416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy.
    Akthar AS; Liao C; Eggener SE; Liauw SL
    Eur Urol; 2019 Nov; 76(5):686-692. PubMed ID: 31113644
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy.
    Jiang NY; Dang AT; Yuan Y; Chu FI; Shabsovich D; King CR; Collins SP; Aghdam N; Suy S; Mantz CA; Miszczyk L; Napieralska A; Namysl-Kaletka A; Bagshaw H; Prionas N; Buyyounouski MK; Jackson WC; Spratt DE; Nickols NG; Steinberg ML; Kupelian PA; Kishan AU
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(3):628-636. PubMed ID: 31276777
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.